ACUT Stock — Accustem Sciences Inc

Accustem Sciences Inc (ACUT)

Updated October 9, 2026.

ACUT is a Stock. Total return is -92.6% over the past 4.6 years, 182.0 points behind SPY at 89.4%.

AccuStem Sciences is a clinical-stage diagnostics company developing genomic tests for oncology care, including an assay to distinguish benign from malignant lung nodules and a prognostic test for breast cancer recurrence risk. The company does not currently have an established distribution schedule. AccuStem appeals to investors seeking exposure to early-stage biotech and diagnostic innovation, though it carries the risks typical of pre-revenue or early-revenue clinical-stage enterprises.

ACUT performance versus SPY

Price and return data through 2026-10-09.

Total return is -92.6% over the past 4.6 years, 182.0 points behind SPY at 89.4%. Over the past year its total return — price change plus distributions reinvested — is -90.5%. Its deepest 1-year drawdown was 92.5%.

ACUT key facts

Asset type

Stock

Asset class

Equity

Inception date

03/02/2022

Distribution frequency

None

Last close

$0.15 (stale; as of 2026-10-09)

Market cap

$2,370,659

Average volume

0.0

Beta

1.891

Payout ratio

0.0%

EPS

$-0.11

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ACUT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 92.5%.

Who may consider ACUT — and who may not

It is a weaker fit for investors who need monthly cash flow (ACUT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ACUT

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions